Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure.

[1]  P. Ghezzi,et al.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Henning,et al.  Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion , 2004, Journal of cardiovascular pharmacology.

[3]  N. Patel,et al.  Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. , 2004, Kidney international.

[4]  D. Allen,et al.  Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. , 2004, Journal of the American Society of Nephrology : JASN.

[5]  J. Pfeilschifter,et al.  Erythropoietin is more than just a promoter of erythropoiesis. , 2004, Journal of the American Society of Nephrology : JASN.

[6]  J. Frøkiaer,et al.  EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. , 2004, Kidney international.

[7]  M. Bogoyevitch.  An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. , 2004, Cardiovascular research.

[8]  N. Patel,et al.  ERYTHROPOIETIN ATTENUATES THE TISSUE INJURY ASSOCIATED WITH HEMORRHAGIC SHOCK AND MYOCARDIAL ISCHEMIA , 2004, Shock.

[9]  John H. Zhang,et al.  Mechanisms of Erythropoietin-induced Brain Protection in Neonatal Hypoxia-Ischemia Rat Model , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  David W. Johnson,et al.  Erythropoietin protects against ischaemic acute renal injury. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  L. Ragolia,et al.  Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. , 2004, Kidney international.

[12]  D. Fliser,et al.  Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin Rapid Communication , 2003 .

[13]  E. Crivellato,et al.  Erythropoietin as an angiogenic factor , 2003, European journal of clinical investigation.

[14]  Chul-woo Yang,et al.  Preconditioning with erythropoietin protects against subsequent ischemia‐reperfusion injury in rat kidney , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  C. Heeschen,et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.

[16]  G. Semenza,et al.  Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia‐Reperfusion Injury , 2003, Circulation.

[17]  Z. Erbayraktar,et al.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Hood,et al.  Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. , 2003, Journal of the American Society of Nephrology : JASN.

[19]  U. Dirnagl,et al.  Erythropoietin Is a Paracrine Mediator of Ischemic Tolerance in the Brain: Evidence from an In Vitro Model , 2002, The Journal of Neuroscience.

[20]  C. Westenfelder.  Unexpected Renal Actions of Erythropoietin , 2002, Nephron Experimental Nephrology.

[21]  K. Kuck,et al.  Erythropoietin and VEGF exhibit equal angiogenic potential. , 2002, Microvascular research.

[22]  P. Lewczuk,et al.  Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.

[23]  D. Rosenbaum,et al.  Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Stuart A. Lipton,et al.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.

[25]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Allegra,et al.  Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. , 2000, European journal of pharmacology.

[28]  I. Macdougall,et al.  Novel erythropoiesis stimulating protein. , 2000, Seminars in nephrology.

[29]  Z. Endre,et al.  Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. , 2000, Journal of the American Society of Nephrology : JASN.

[30]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[31]  F. Prósper,et al.  Erythropoietin Can Induce the Expression of Bcl-xLthrough Stat5 in Erythropoietin-dependent Progenitor Cell Lines* , 1999, The Journal of Biological Chemistry.

[32]  S. Orkin,et al.  GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. , 1999, Blood.

[33]  E. Mackenzie,et al.  A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  Roger A. Kaiser,et al.  Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. , 1999, Kidney international.

[35]  D. Altavilla,et al.  Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock , 1999, British journal of pharmacology.

[36]  D. Power,et al.  Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. , 1999, Clinical and experimental pharmacology & physiology. Supplement.

[37]  C. Westenfelder,et al.  Human, rat, and mouse kidney cells express functional erythropoietin receptors. , 1999, Kidney international.

[38]  Y. Asano,et al.  Human recombinant erythropoietin inhibits interleukin-1beta-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  F. Schena.  Role of growth factors in acute renal failure. , 1998, Kidney international. Supplement.

[40]  E. Morishita,et al.  In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Eckardt,et al.  Erythropoietin production in rats with post-ischemic acute renal failure. , 1996, Kidney international.

[42]  M. Le Hir,et al.  Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[43]  O. Nielsen,et al.  Erythropoietin deficiency in acute tubular necrosis , 1990, Journal of internal medicine.

[44]  J. Kerr,et al.  Anatomical methods in cell death. , 1995, Methods in cell biology.